AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Amicus Therapeutics (FOLD) Soars 10.05% on Japan Approval
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Jul 17, 2025 6:48 am ET1min read
Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported that it received approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of Pompe disease in Japan, which has led to a 10.05% rise in pre-market trading on July 17, 2025.
Amicus Therapeutics has adjusted its 2025 total revenue growth guidance to 15-22% and lowered expectations for Pombiliti + Opfolda growth. The company also reiterated its commitment to advancing its pipeline and expanding its commercial footprint.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Serve Robotics Surges 5.16% as Trump Admin Boosts Robotics Push, Eyes 10X Revenue by 2026
Dec.12 2025
New Pacific Metals (NPM) Soars 7.98% as Base Metals Market Anticipates Supply/Demand Shifts
Dec.12 2025
Gevo Inc. (GEVO) Surges 6.22% on $26M BioRecro Partnership to Expand Carbon Management Capabilities
Dec.12 2025
Sable Offshore Soars 5.82% as Private Placement and Policy Tailwinds Drive Pre-Market Rally
Dec.12 2025
Mastercard Inc. Surges 4.55% as Fintech Optimism and AI Expansion Drive Pre-Market Rally
Dec.12 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet